[The trend toward development of novel agents based on the mechanism of prostate cancer progression].
Department of Urology, Iwate Medical University, School of Medicine.
Kazuhiro
K
Iwasaki
Wataru
W
Obara
Tomoaki
T
Fujioka
D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
D000730:Androstadienes; D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D009570:Nitriles; D043823:Taxoids; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C511774:sipuleucel-T; C540278:enzalutamide; D000069501:Abiraterone Acetate